Not a good buy right now for an impatient trader: momentum is still bearish (MACD below zero) and there are no Intellectia entry signals.
The stock is extremely oversold (RSI-6 16) and sitting near support (3.06), so a short-term bounce is possible, but it’s not a high-confidence entry without a confirmed reversal.
With no fresh news catalysts and earnings upcoming (2026-02-12 pre-market), the near-term move is more likely driven by volatility than a clear trend setup.
Technical Analysis
Price action: Regular session -6.27% and post-market 3.10, hovering just above S1 support (3.057). A break below S1 opens room toward S2 (2.689).
RSI: RSI_6 at ~16.27 signals deeply oversold conditions (bounce potential), but oversold alone is not a trend reversal.
MACD: Histogram at -0.111 (below 0) and negatively contracting, implying bearish momentum still present though selling pressure may be easing.
Moving averages: Converging MAs suggests the downtrend may be slowing, but not yet flipping to a clear uptrend.
Key levels: Pivot 3.653 (reclaiming above improves bullish odds). Resistance at 4.249 (R1) then 4.617 (R2).
Gross margin: 100 (flat YoY), indicates very high reported margin but does not offset the YoY decline in earnings metrics.
Next known catalyst date: QDEC 2025 earnings on 2026-02-12 (pre-market).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data provided, so recent Wall Street trend cannot be confirmed.
Wall Street pros/cons view based on available data only: Pros—sharp revenue growth and potential oversold rebound setup. Cons—deteriorating YoY earnings and still-bearish technical momentum, with no clear institutional/insider buying trend indicated.
Politicians/congress: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is 12.33 USD with a low forecast of 10 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is 12.33 USD with a low forecast of 10 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.910
Low
10
Averages
12.33
High
16
Current: 2.910
Low
10
Averages
12.33
High
16
JonesResearch
NULL -> Buy
initiated
$10
AI Analysis
2025-10-29
Reason
JonesResearch
Price Target
$10
AI Analysis
2025-10-29
initiated
NULL -> Buy
Reason
JonesResearch initiated coverage of Evaxion Biotech with a Buy rating and $10 price target. The firm says Evaxion is a clinical-stage company leveraging its AIdriven platform to develop vaccines. The company's Phase 2 data in melanoma showed a durable clinical benefit and sustained immune response at the two-year cutoff, the analyst tells investors in a research note.
Lake Street
Thomas Flaten
Buy
maintain
$6 -> $11
2025-10-20
Reason
Lake Street
Thomas Flaten
Price Target
$6 -> $11
2025-10-20
maintain
Buy
Reason
Lake Street analyst Thomas Flaten raised the firm's price target on Evaxion Biotech (EVAX) to $11 from $6 and keeps a Buy rating on the shares after the company announced two-year Phase 2 data for its personalized cancer vaccine, EVX-01, in advanced melanoma. The two-year EVX-01 data and Merck's (MRK) option exercise for EVX-B3 further validate Evaxion's platform, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVAX
